Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 before prostatectomy in high-risk localized prostate cancer
ACTRN12614000789662Phase 2Not yet recruiting
- Sponsor
- The University of Sydney
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Luminespib in prostate cancer (PCa), sponsored by The University of Sydney. Primary endpoint: Tumor cell proliferation by Ki-67 reduction. Planned start Aug 2016; status: not yet recruiting.
02
Drugs
Luminespib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12614000789662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000789662.